These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 15557494)

  • 1. Epileptic seizures in systemic lupus erythematosus.
    Appenzeller S; Cendes F; Costallat LT
    Neurology; 2004 Nov; 63(10):1808-12. PubMed ID: 15557494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies.
    Hachulla E; Michon-Pasturel U; Leys D; Pruvo JP; Queyrel V; Masy E; Arvieux J; Caron C; Brevet-Coupé F; Hatron PY; Devulder B
    Lupus; 1998; 7(2):124-31. PubMed ID: 9541097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus.
    Campos LM; Kiss MH; D'Amico EA; Silva CA
    Lupus; 2003; 12(11):820-6. PubMed ID: 14667097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome.
    Gattorno M; Buoncompagni A; Molinari AC; Barbano GC; Morreale G; Stalla F; Picco P; Mori PG; Pistoia V
    Br J Rheumatol; 1995 Sep; 34(9):873-81. PubMed ID: 7582730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up.
    Gerhardsson J; Sundelin B; Zickert A; Padyukov L; Svenungsson E; Gunnarsson I
    Arthritis Res Ther; 2015 Apr; 17(1):109. PubMed ID: 25927214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
    Domingues V; Chock EY; Dufrost V; Risse J; Seshan SV; Barbhaiya M; Sartelet H; Erkan D; Wahl D; Zuily S
    Autoimmun Rev; 2022 Oct; 21(10):103158. PubMed ID: 35907609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus.
    Herranz MT; Rivier G; Khamashta MA; Blaser KU; Hughes GR
    Arthritis Rheum; 1994 Apr; 37(4):568-71. PubMed ID: 8147935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus.
    Woo KS; Kim KE; Kim JM; Han JY; Chung WT; Kim KH
    Korean J Lab Med; 2010 Feb; 30(1):38-44. PubMed ID: 20197721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical description of seizures in patients with systemic lupus erythematosus.
    González-Duarte A; Cantú-Brito CG; Ruano-Calderón L; García-Ramos G
    Eur Neurol; 2008; 59(6):320-3. PubMed ID: 18408374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibody tests: spreading the net.
    Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
    Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative analysis of clinical and laboratory charactiristics of antiphospholipid syndrome].
    Soltész P; Veres K; Kiss E; Lakos G; Sonkoly I; Muszbek L; Szegedi G
    Orv Hetil; 2000 Dec; 141(52):2821-5. PubMed ID: 11202118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus.
    Taraborelli M; Lazzaroni MG; Martinazzi N; Fredi M; Cavazzana I; Franceschini F; Tincani A
    Reumatismo; 2016 Dec; 68(3):137-143. PubMed ID: 27981815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?
    Mok MY; Farewell VT; Isenberg DA
    Ann Rheum Dis; 2000 Jun; 59(6):462-7. PubMed ID: 10834864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of antiphospholipid antibodies in lupus nephritis.
    Natejumnong C; Ruangkanchanasetr P; Aimpun P; Supaporn T
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S121-8. PubMed ID: 17044463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study.
    Perez-Villa F; Font J; Azqueta M; Espinosa G; Pare C; Cervera R; Reverter JC; Ingelmo M; Sanz G
    Arthritis Rheum; 2005 Jun; 53(3):460-7. PubMed ID: 15934103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.
    Wahl DG; Guillemin F; de Maistre E; Perret C; Lecompte T; Thibaut G
    Lupus; 1997; 6(5):467-73. PubMed ID: 9229367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of antiphospholipid antibodies in patients with overt myocardial dysfunction in systemic lupus erythematosus. A case-control study.
    Gawalkar AA; Bahl A; Ahluwalia J; Sood A; Sharma A; Sharma S; Dhir V
    Lupus; 2020 Oct; 29(12):1503-1508. PubMed ID: 32752919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus.
    Picceli VF; Skare TL; Nisihara RM; Nass FR; Messias-Reason IT; Utiyama SR
    Lupus; 2016 Apr; 25(4):412-7. PubMed ID: 26537423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.